Long‐term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.

The article presents a study that investigated if a pattern of molecular response (MR) instability could affect overall survival (OS) and failure-free survival in a series of chronic myeloid leukaemia(CP-CML) patients who received imatinib for a median follow-up of 7 years. Topics discussed include analysis of the patients for mutational screening with Sanger sequencing analysis and the association of MR3 with increased probability of developing resistance to imatinib.